|
|
DSpace at RU >
Browsing by Author Hagen, T.L.M. ten
Showing results 1 to 11 of 11
| Full Text | Issue Date | Title | Author(s) | | 2011 | Crossing barriers: the new dimension of 2D cell migration assays. | Horssen, R. van; Hagen, T.L.M. ten |
| 2010 | Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. | Bouwhuis, M.G.; Suciu, S.; Testori, A.; Kruit, W.H.; Sales, F., et al |
| 2009 | Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. | Bouwhuis, M.G.; Suciu, S.; Collette, S.; Aamdal, S.; Kruit, W.H., et al |
| 2009 | Modulation of cell motility by spatial repositioning of enzymatic ATP/ADP exchange capacity. | Horssen, R. van; Janssen, E.E.W.; Peters, W.J.M; Pasch, L. van de; Lindert, M.M., et al |
| 2008 | Cytokine detection in cells and tissues: complicated lessons from proEMAP/p43 and EMAP-II. | Horssen, R. van; Rens, J.A.; Hagen, T.L.M. ten |
| 2006 | Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. | Horssen, R. van; Eggermont, A.M.M.; Hagen, T.L.M. ten |
| 2006 | Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. | Horssen, R. van; Rens, J.A.; Brunstein, F.; Guns, V.; Gils, M. van, et al |
| 2006 | TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. | Horssen, R. van; Hagen, T.L.M. ten; Eggermont, A.M.M. |
| 2006 | EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization. | Horssen, R. van; Rens, J.A.; Schipper, D.; Eggermont, A.M.M.; Hagen, T.L.M. ten |
| 2006 | Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay. | Horssen, R. van; Galjart, N.; Rens, J.A.; Eggermont, A.M.M.; Hagen, T.L.M. ten |
| 2004 | Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. | Brouckaert, P.; Takahashi, N.; Tiel, S.T.; Hostens, J.; Eggermont, A.M.M., et al |
Showing results 1 to 11 of 11
|